SCHEMBL11143333

SCHEMBL11143333

CN(C)c1cccc2cnccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.53
LMNA P02545 3/20 0.53
CYP3A4 P08684 2/20 0.53
CYP2D6 P10635 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
MAPKAPK2 P49137 1/20 0.53
HTT P42858 1/20 0.49
MAPT P10636 3/20 0.47
GAA P10253 1/20 0.47
MCL1 Q07820 1/20 0.44
LATS1 O95835 1/20 0.44
LATS2 Q9NRM7 1/20 0.44
TRPV1 Q8NER1 1/20 0.42
ROCK2 O75116 3/20 0.42
ROCK1 Q13464 3/20 0.42
ALDH1A1 P00352 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21401740 0.85 TNF (0.49) KDM4ELMNACYP3A4CYP2D6CYP1A2
SCHEMBL28643684 0.80 LATS1 (0.42) KDM4ELMNACYP3A4CYP2D6CYP1A2
SCHEMBL4025912 0.80 KDM4E (0.49) KDM4ELMNACYP3A4CYP2D6CYP1A2
SCHEMBL2359679 0.79 KDM4E (0.47) KDM4ELMNACYP3A4CYP2D6CYP1A2
SCHEMBL16484721 0.77 CYP3A4 (0.49) KDM4ELMNACYP3A4CYP2D6CYP1A2
SCHEMBL11140810 0.76 PRKCZ (0.42) KDM4ECYP3A4CYP2D6CYP1A2CYP2C9
Pyridine SCHEMBL31317041 0.76 SIGMAR1 (0.50) KDM4ELMNACYP3A4CYP2D6CYP1A2
SCHEMBL29555314 0.74 SIGMAR1 (0.63) KDM4ECYP2D6CYP1A2CYP2C19MAPT
SCHEMBL29364795 0.74 SIGMAR1 (0.63) KDM4ECYP2D6CYP1A2CYP2C19MAPT
SCHEMBL27737084 0.74 SIGMAR1 (0.63) KDM4ECYP2D6CYP1A2CYP2C19MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10864217-B2 Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy Sanford Burnham Prebys Medical Discovery Institute (US) 2020-12-15 US disclosed
US-20200121693-A1 Use of Inhibitor of Apoptosis Protein (IAP) Antagonists in HIV Therapy SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE 2020-04-23 US disclosed
US-9782408-B2 Modulators of cystic fibrosis transmembrane conductance regulator VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-10-10 US disclosed
US-20170196862-A2 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-07-13 US disclosed
US-4396619-A ANTIBIOTICS ELI LILLY AND COMPANY (US) 1983-08-02 US disclosed
US-4382932-A Isoquinolinium substituted cephalosporins ELI LILLY AND COMPANY (US) 1983-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10864217-B2 Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy API5, BIRC3, BIRC5 KDM4E 3126/4885LMNA 2103/4885CYP3A4 4373/4885
US-20200121693-A1 Use of Inhibitor of Apoptosis Protein (IAP) Antagonists in HIV Therapy API5, BIRC3, BIRC5 KDM4E 3126/4885LMNA 2103/4885CYP3A4 4373/4885
US-20170196862-A2 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1B, SLC26A4 KDM4E 2973/4885LMNA 3018/4885CYP3A4 3432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.